XVIVO acquires unique communication platform for the transplantation process Page 1

GOTHENBURG, SWEDEN / ACCESSWIRE / September 19, 2024 / Today, XVIVO Perfusion AB (publ) (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (“XVIVO” or “the Company”) entered into an agreement to acquire the transplant clinical workflow automation business, which includes the development and distribution of the FlowHawkTM software platform, from Healthtech Solutions Inc. dba OmniLife. Organ transplantation is a complex, life-dependent process where flawless communication, both internally and externally, is critical for transplant centers and the transplant ecosystem. With the acquisition of FlowHawk, XVIVO strengthens its service offering in the U.S., simplifying planning and communication throughout the transplant process for its customers.

The increasingly complex and rapidly changing transplant system in the United States requires new tools and support systems to better enable transplant teams to manage critical activities during the transplant process. Today, transplant centers must often rely on traditional text messages, emails, and phone calls for communication—which can be burdensome and inefficient. Transplant centers need ways to lower barriers and streamline processes to continue increasing transplant procedures. FlowHawk software enables direct HIPAA-compliant communication with relevant teams, delivering the right information to the right people at the right time. Simple, transparent, and trackable workflows ensure all relevant tasks are completed and decisions are recorded.

With this acquisition, XVIVO is building for the future. The FlowHawk software has an established footprint among leading transplant centers in the US and XVIVO is confident that the solution can be made available to many more transplant centers, building on the already proven commercial success of OmniLife. XVIVO expects the acquisition to have a positive impact on service revenues in the US and FlowHawk will play a central role in the beyond product offering.

“One of our strategic focus areas is to become the preferred partner in the transplant process, and this acquisition brings us closer to that goal. Our organ recovery service in the US already uses FlowHawk and we are eager to offer this solution to more customers. We share a common goal with our customers: more patients should receive the transplants they desperately need. To achieve this, we need to support transplant centers with services that reduce barriers. Our vision is clear: ‘No one should die waiting for a new organ’,” says Christoffer Rosenblad, CEO of XVIVO.